Adagio Therapeutics Reports First Quarter 2022 Financial Results

Go back to Adagio Therapeutics Reports First Quarter 2022 Financial Results

Adagio (ADGI) PT Lowered to $5 at Stifel

May 13, 2022 1:29 PM EDT

Stifel analyst Stephen Willey lowered the price target on Adagio (NASDAQ: ADGI) to $5.00 (from $9.00) while maintaining a Hold rating.

... More